This book contains the contributions to the 30th Hemophilia Symposium, 1999. The main topics are HIV infection, inhibitors in hemophilia, modern treatment of hemophilia, drug-induced thrombophilia and pediatric hemostasiology. The volume is rounded off by numerous free papers and posters on hemophilia and associated topics.

I. HIV Infection and Epidemiology in Hemophilia

Causes of Death and AIDS-Related Disease of Hemophilia Patients in Germany (Inquiries 1999)
II. Gene Therapy in Hemophilia
Genotype-Phenotype Correlation in Hemophilia A
III. Therapy of Hepatitis C
Current Therapy of Hepatitis C Virus Infection
Interferon Alpha-2a Treatment in Patients with Hepatitis C and Bleeding Disorders
Report on Experience in the Treatment of Hepatitis C in HIV-Coinfected Hemophiliacs
IV. Inhibitors in Hemophilia
A New Therapeutic Option for Inhibitor Elimination in Patients with Acquired Hemophilia
V. Long-Term Results After Joint Replacement
Long-Term Results After Total Knee and Total Hip Replacement in Hemophilie Arthropathy
Total Knee Prosthesis in Hemophiliacs with Multilocular Hemophilie Arthropathy-The Zurich Experience
Corrective Osteotomy of the Lower Extremity in Hemophilie Arthropathy of the Knee and Hip Joint
VI. Pediatrie Hemostasiology
Anticoagulant Action of Activated Protein C is Diminished by Alpha2-Macroglobulin in Newborn Plasma
Functional Consequences of Differences in Carbohydrate Sequences of Fetal and Adult Plasminogen and Fibrinogen
Hereditary Thrombophilic Risk Profiles in Children with Spontaneous Venous Thromboembolism
Inhibitor Development in Previously Untreated Patients with Hemophilia A and B: A Prospective 23-Year Follow-Up
HIT Type II without Thrombocytopenia in a 15-Year-Old Boy with Protein S Deficiency and Recurrent Deep Vein Thrombosis
VII. Free Lectures
Modified Bonn-Malmö Protocol
A Novel Type of Mutation at the Propeptide Cleavage Site (Ala+lThr) Causing Symptomatic Protein C Type II Deficiency
Lithuanian Hemophilia A and B Register Comprising Phenotypic and Genotypic Data
Greifswald Hemophilia B Study
Successful Treatment of Patients with von Willebrand Disease Using a High-Purity Double Virus Inactivated FVIII/vWF Concentrate (IMMUNATE)
VIII. Research Cooperation
Industry Sponsoring and Acceptance of Benefit by Hospital Officials: Opportunities and Limits of Third-Party Funding
IX.a Poster: Hemophilia
Experience with Recombinant Factor IX (Benefix) in Pediatrics
Articular Cartilage Is More Susceptible to Blood-Induced Damage in Young Than in Old Age
Chronic Liver Disease in Hemophilia Patients
Human Immunodeficiency Virus-Negative "High-Risk Patients" with Hemophilia or Severe von Willebrand Disease Type 3: Coincidence or Genetics?
Quality Management and Economic Aspects in Hemotherapy in the Federal Republic of Germany: Description of a Retrospective Cross-Sectional Multicenter Trial
How Hemophiliacs View the Services Offered by "Bluter Betreuung Bayern e.V."
Alpha-Tocopherol - A Medication with Few Side Effects for Treating Pain in Patients with Hemarthrosis
Neurosensorial Sequelae in Hemophilia
IX.b Poster: Thrombophilia
Effect of Vitamin Supplementation in Venous Thrombosis Patients with Hyperhomocysteinemia
Therapy and Prophylaxis of the Thromboembolic Syndrome in Pregnancy and Post Delivery
Is Factor V Leiden Associated with an Increased Risk for Fetal Loss?
IX.c Poster: Molecular Biology
Congenital Deficiency of Vitamin K Dependent Coagulation Factors in Two Families: Evidence for a Defective Vitamin K-Epoxide-Reductase Complex
Twenty-Two Novel Mutations of Factor VII Gene in Factor VII Deficiency
Prevalence of Common Mutations and Polymorphisms of the Genes of FII, FV, FVII, FXII, FXIII, MTHFR and ACE - Identified As Risk Factors for Venous and Arterial Thrombosis - in Germany and Different Ethnic Groups (Indians, Blacks) of Costa Rica
Factor V Variants - FV Leiden, FV R2 Polymorphism (ex 13), FV DdeI Polymorphism (int 16) -- Risk Factors for Venous Thrombosis? Results of a Pilot Study
Relation Between Prothrombin Mutation 20210 G?A, Prothrombin Time, Factor V Leiden and Prothrombin Level
Localization and Characterization of Mutations within the Factor-VIII-Gene in a Cohort of 212 Patients with Hemophilia A
Genomic Diagnosis of Hemophilia A in Hungarian Patients
Indirect Genomic Diagnosis of Hungarian Hemophilia B Patients
IX.d Poster: Pediatrics
Relation of Cardiovascular Fitness, Hemostatic and Metabolic Risk Factors for Coronary Heart Disease in Obese Children and Adolescents
Inverse Correlation Between Thyroid Function and Hemostatic Risk Factors for Coronary Heart Disease in Obese Children and Adolescents
Heparin-Induced Thrombocytopenia Type II in Three Children and Anticoagulant Therapy with Org 10172 (Orgaran)
Heparin Concentration, Activated Clotting Time, and Markers of Coagulation Activation During Pediatrie Heart Catheterization
Therapeutic Options in Immune Thrombocytopenic Purpura in Childhood
Camps for Children and Young Adults with Hemophilia in Germany, Austria, and Switzerland
Clinical Experience with the PFA-100 System in Children and Adolescents
Endothelial Activation Markers in Health and Disease - Big Endothelin-1 and Endothelin-1 in Children
IX.e Poster: Case Reports
Dramatic Intra-Abdominal Bleeding - First Symptom of Hemophilia B in a Neonate
Postoperative Bleeding in a Sufficiently Substituted Patient with Severe Hemophilia A: Successful Therapy with Administration of Recombinant Factor VIIa
Continuous Infusion of Recombinant FIX (BeneFIX) During Herniotomy in an Infant
Clinical Course of Intramuscular Bleeds in a Patient with Factor-XIII Deficiency
Immunthrombocytopenia and Lupus Antibodies in a Patient with Hemophilia A
Cerebral Sinus Thrombosis After Asparaginase Therapy
Severe Neonatal Thrombosis in a Patient with Factor V Q:506 Mutation and the G20210A Prothrombin Mutation
Elevated Lp(a) Level and Heterozygous Factor V Mutation FV 1691 AG in a 26-Year-Old Female with Ischemic Colitis
Acquired Hemophilia in Women Postpartum
IX.f Poster: Hemorrhagic Disorders
Modulation of Antigens of Neutrophil Granulocytes by Extracorporal Apheresis
Glycoprotein Ilb/IIIa Receptor Antagonist c7E3 Fab and Anticoagulants Show an Additive Effect on Thrombin-Induced Platelet Aggregation after High Coagulant Challenge In Vitro
Between-Drug Comparison of the Effect of Ticlopidine and Acetylsalicylic Acid on Platelets in an In Vitro Circulation Model
Rotablation Leads to Significant Platelet Activation: A Flow Cytometric Assessment
Flow Cytometric Comparison of Platelet Activation During PTCA, Stent Implantation and Rotablation
Analysis of Hemostatic Capacity before and after Extracorporal Platelet-Pheresis by the PFA-100 Test System
Heparin Coating of Coronary Stents Increases Time Until Stent Occlusion Due to Delayed Platelet Activation in an In Vitro Circulating Model
High-Speed Detection of Human Progenitor Cells (HPC) to Support the Timing of Aphereses
Semi-Automated Flow Cytometry Can Help in Timing the Onset of Stem-Cell Leukapheresis
IX.g Poster: Diagnostic Problems
Current Topics of Official Batch Release: Determination of FXIII Activity in Fibrin Glues and FXIII Concentrates and Measurement of Heparin/AT Complexes in FVIII Products
Comparison of BVDV and SFV Used as Models for Hepatitis C Virus in Virus Validation Studies
Preoperative Coagulation Screening in Children Focused on PTT Elevation
Resonance Thrombographic Analysis of Coagulation Status after Transfusion of Platelet Concentrates with Different Storage Times.